Karyopharm Therapeutics Inc
(NAS:KPTI)
$
0.6763
-0.0238 (-3.4%)
Market Cap: 85.34 Mil
Enterprise Value: 149.08 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 68/100 Karyopharm Therapeutics Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 09, 2021 / 02:10PM GMT
Release Date Price:
$11.48
(+3.52%)
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst
Great. Thank you. Good morning, everyone. Welcome to Barclays Global Healthcare Conference. My name is Peter Lawson. I'm one of the biotech equity analysts at Barclays. I just want to thank everyone for taking the time out of the day. I've got a series of questions, but do ping me by e-mail, so it's [email protected] or ping me on Bloomberg.
It gives me a great pleasure to introduce the management team from Karyopharm today. I've got Michael Kauffman and various other members of management team as well on the line.
Questions & Answers
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst
And so maybe it's just an opening question as kind of a 2- to 3-minute kind of overview kind of the company's differentiation in the oncology space, what would you kind of define as Karyopharm's core competencies?
Michael G. Kauffman
Karyopharm Therapeutics Inc. - Co-Founder, CEO & Director
Yes. Well
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot